{"id":1490,"date":"2026-11-05T11:53:13","date_gmt":"2026-11-05T10:53:13","guid":{"rendered":"https:\/\/epilogy.org\/?p=1490"},"modified":"2026-11-05T12:12:03","modified_gmt":"2026-11-05T11:12:03","slug":"risk-of-cancer-according-to-duration-of-targeted-therapy-exposure-in-spondyloarthritis-a-nationwide-cohort-study-from-the-french-health-insurance-database-in-arthritis-rheumatology","status":"publish","type":"post","link":"https:\/\/epilogy.org\/fr\/risk-of-cancer-according-to-duration-of-targeted-therapy-exposure-in-spondyloarthritis-a-nationwide-cohort-study-from-the-french-health-insurance-database-in-arthritis-rheumatology","title":{"rendered":"Risque de cancer selon la dur\u00e9e d'exposition aux th\u00e9rapies cibl\u00e9es dans les spondyloarthrites : une \u00e9tude de cohorte nationale issue de la base de donn\u00e9es de l'Assurance maladie, dans Arthritis &#038; Rheumatology"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"1490\" class=\"elementor elementor-1490 elementor-bc-flex-widget\">\n\t\t\t\t<div class=\"elementor-element elementor-element-eb875c7 e-flex e-con-boxed e-con e-parent\" data-id=\"eb875c7\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-3726e29 elementor-widget elementor-widget-html\" data-id=\"3726e29\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t\t<style>\n.epilogy-accordion{\nbackground:#ffffff;\nborder:1px solid #ead3ee;\nborder-radius:8px;\npadding:20px;\nmargin:24px 0;\nfont-size:13px;\ncolor:#54595F;\nline-height:1.7;\nbox-shadow:0 2px 8px rgba(0,0,0,0.04);\n}\n\n.epilogy-accordion details{\nborder-top:1px solid #eee;\npadding:10px 0;\n}\n\n.epilogy-accordion details:first-of-type{\nborder-top:none;\n}\n\n.epilogy-accordion summary{\ncursor:pointer;\nfont-weight:600;\ncolor:#7C2A86;\nfont-size:13px;\nlist-style:none;\nposition:relative;\npadding-left:18px;\n}\n\n.epilogy-accordion summary::before{\ncontent:\"+\";\nposition:absolute;\nleft:0;\ntop:0;\n}\n\n.epilogy-accordion details[open] summary::before{\ncontent:\"\u2013\";\n}\n\n.epilogy-highlight{\nbackground:#FADFFF;\npadding:14px;\nborder-radius:6px;\nmargin-top:18px;\nfont-size:13px;\nborder-left:4px solid #7C2A86;\n}\n\n.epilogy-highlight h3{\nmargin:0 0 6px 0;\ncolor:#7C2A86;\nfont-size:13px;\n}\n\n.epilogy-highlight a{\nfont-size:12px;\nopacity:0.9;\n}\n\n.epilogy-authors{\nmargin-top:20px;\npadding-top:14px;\nborder-top:1px solid #eee;\n}\n\n.epilogy-authors-title{\nfont-weight:600;\ncolor:#7C2A86;\nmargin-bottom:10px;\n}\n\n.epilogy-authors-grid{\ndisplay:grid;\ngrid-template-columns:repeat(3,1fr);\ngap:10px;\ntext-align:center;\njustify-items:center;\n}\n\n.epilogy-authors-grid img{\nwidth:70px;\nheight:70px;\nobject-fit:cover;\nborder-radius:100%;\ntransition:all .2s ease;\n}\n\n\n.epilogy-authors-grid span{\ndisplay:block;\nmargin-top:6px;\nfont-size:12px;\n}\n<\/style>\n\n<div class=\"epilogy-accordion\">\n\n<details open>\n<summary>Objective<\/summary>\n<p>\nTo assess the association between duration of targeted therapy exposure and cancer risk in patients with spondyloarthritis (SpA), including those with psoriatic arthritis, axial SpA, and other subtypes.\n<\/p>\n<\/details>\n\n<details>\n<summary>Methods<\/summary>\n<p>\nThis nationwide cohort study used the French health insurance database to identify adults with SpA initiating a targeted therapy (tumor necrosis factor inhibitors [TNFi], interleukin-17 inhibitors [IL-17i], IL-12\/23i, IL-23i, JAK inhibitors [JAKi]) from January 2014 to September 2022. Patients with prior cancer, HIV infection, or organ transplantation were excluded. Follow-up began after a three-month delay and continued until December 2024. Exposure was assessed annually and classified as \u22646 or &gt;6 months per year. Incident cancer was the primary outcome. Weighted Cox marginal structural models with inverse probability of treatment and censoring weights were used. A post hoc sensitivity analysis evaluated cumulative exposure trajectories over time.\n<\/p>\n<\/details>\n\n<details>\n<summary>Results<\/summary>\n<p>\nWe included 56,591 patients (53.9% women; mean \u00b1 SD age 44 \u00b1 13 years; median follow-up 5.0 years). During follow-up, 1,224 cancers occurred (1,029 solid, 116 hematological, 79 unclassified). Exposure &gt;6 months versus \u22646 months was associated with a lower risk of overall cancer (weighted hazard ratio [wHR] 0.86, 95% confidence interval [CI] 0.75-0.99). In subgroup analyses, this association was observed for hematological malignancies (wHR 0.65, 95% CI 0.42-0.99) but not for solid cancers (wHR 0.92, 95% CI 0.79-1.07). Cumulative exposure history was not associated with cancer risk.\n<\/p>\n<\/details>\n\n<details>\n<summary>Conclusion<\/summary>\n<p>\nIn this nationwide study, prolonged exposure to targeted therapies was not associated with an increased cancer risk. Exposure &gt;6 months per year was associated with a lower cancer risk, mainly for hematological malignancies, whereas cumulative exposure over multiple years was not associated with cancer risk.\n<\/p>\n<\/details>\n\n<div class=\"epilogy-authors\">\n<div class=\"epilogy-authors-title\">Author from the Epilogy team<\/div>\n\n<div class=\"epilogy-authors-grid\">\n<div>\n<img decoding=\"async\" src=\"https:\/\/epilogy.org\/wp-content\/uploads\/2026\/04\/Karine_Tankovic.png\" alt=\"Karine Tankovic\">\n<span>Karine Tankovic<\/span>\n<\/div>\n<\/div>\n<\/div>\n\n<div class=\"epilogy-highlight\">\n<h3>Risk of Cancer According to Duration of Targeted Therapy Exposure in Spondyloarthritis: A Nationwide Cohort Study From the French Health Insurance Database<\/h3>\n<p style=\"margin:0;\">\n<a href=\"https:\/\/doi.org\/10.1002\/art.70297\" target=\"_blank\">\nhttps:\/\/doi.org\/10.1002\/art.70297\n<\/a>\n<\/p>\n<\/div>\n\n<\/div>\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-8aea6a5 e-flex e-con-boxed e-con e-parent\" data-id=\"8aea6a5\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-e312a9b elementor-widget elementor-widget-html\" data-id=\"e312a9b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t\t<script>\ndocument.querySelectorAll('.epilogy-accordion details').forEach((detail) => {\n  detail.addEventListener('toggle', function() {\n    if (this.open) {\n      document.querySelectorAll('.epilogy-accordion details').forEach((other) => {\n        if (other !== this) {\n          other.removeAttribute('open');\n        }\n      });\n    }\n  });\n});\n<\/script>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Objective To assess the association between duration of targeted therapy exposure and cancer risk in patients with spondyloarthritis (SpA), including those with psoriatic arthritis, axial SpA, and other subtypes. Methods This nationwide cohort study used the French health insurance database to identify adults with SpA initiating a targeted therapy (tumor necrosis factor inhibitors [TNFi], interleukin-17&hellip;&nbsp;<a href=\"https:\/\/epilogy.org\/fr\/risk-of-cancer-according-to-duration-of-targeted-therapy-exposure-in-spondyloarthritis-a-nationwide-cohort-study-from-the-french-health-insurance-database-in-arthritis-rheumatology\" rel=\"bookmark\"><span class=\"screen-reader-text\">Risk of Cancer According to Duration of Targeted Therapy Exposure in Spondyloarthritis: A Nationwide Cohort Study From the French Health Insurance Database in Arthritis &#038; Rheumatology<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":1489,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"off","neve_meta_content_width":70,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","neve_meta_reading_time":"","footnotes":""},"categories":[1,18,20],"tags":[],"class_list":["post-1490","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-epilogy","category-epinews","category-last-publications"],"_links":{"self":[{"href":"https:\/\/epilogy.org\/fr\/wp-json\/wp\/v2\/posts\/1490","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/epilogy.org\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/epilogy.org\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/epilogy.org\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/epilogy.org\/fr\/wp-json\/wp\/v2\/comments?post=1490"}],"version-history":[{"count":3,"href":"https:\/\/epilogy.org\/fr\/wp-json\/wp\/v2\/posts\/1490\/revisions"}],"predecessor-version":[{"id":1493,"href":"https:\/\/epilogy.org\/fr\/wp-json\/wp\/v2\/posts\/1490\/revisions\/1493"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/epilogy.org\/fr\/wp-json\/wp\/v2\/media\/1489"}],"wp:attachment":[{"href":"https:\/\/epilogy.org\/fr\/wp-json\/wp\/v2\/media?parent=1490"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/epilogy.org\/fr\/wp-json\/wp\/v2\/categories?post=1490"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/epilogy.org\/fr\/wp-json\/wp\/v2\/tags?post=1490"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}